128 related articles for article (PubMed ID: 8352566)
1. The reversal of multidrug resistance in cancer (review).
Kellen JA
Anticancer Res; 1993; 13(4):959-61. PubMed ID: 8352566
[TBL] [Abstract][Full Text] [Related]
2. Molecular interrelationships in multidrug resistance (review).
Kellen JA
Anticancer Res; 1994; 14(2A):433-5. PubMed ID: 8017843
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance in cancer: its mechanism and its modulation.
Pauwels EK; Erba P; Mariani G; Gomes CM
Drug News Perspect; 2007; 20(6):371-7. PubMed ID: 17925891
[TBL] [Abstract][Full Text] [Related]
4. Cancer chemotherapy. Progress in understanding multidrug resistance.
Stark GR
Nature; 1986 Dec 4-10; 324(6096):407-8. PubMed ID: 2878367
[No Abstract] [Full Text] [Related]
5. Integrins and extracellular matrix: a novel mechanism of multidrug resistance.
Elliott T; Sethi T
Expert Rev Anticancer Ther; 2002 Aug; 2(4):449-59. PubMed ID: 12647988
[TBL] [Abstract][Full Text] [Related]
6. [Resistance and resistances].
Cappelaere P
Bull Cancer; 1994 Dec; 81 Suppl 2():115s-117s. PubMed ID: 7727857
[TBL] [Abstract][Full Text] [Related]
7. [Drug resistance and a strategy to eradicate resistant malignant cells].
Shimoyama M
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1280-2. PubMed ID: 2730026
[TBL] [Abstract][Full Text] [Related]
8. [Multidrug resistance].
Donenko FV; Sitdikova SM; Moroz LV
Vopr Onkol; 1991; 37(7-8):780-8. PubMed ID: 1842629
[No Abstract] [Full Text] [Related]
9. [Resistance to antineoplastic treatments: mechanisms, clinical value].
Bonnal C; Calvo F
C R Seances Soc Biol Fil; 1996; 190(4):455-66. PubMed ID: 8952896
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance.
Shibata H; Kanamaru R; Sato T; Ishioka C; Suzuki T; Wakui A
Sci Rep Res Inst Tohoku Univ Med; 1990 Dec; 37(1-4):27-50. PubMed ID: 2103657
[No Abstract] [Full Text] [Related]
11. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance reversal agents.
Robert J; Jarry C
J Med Chem; 2003 Nov; 46(23):4805-17. PubMed ID: 14584929
[No Abstract] [Full Text] [Related]
13. Synthesis and biochemical characterization of new phenothiazines and related drugs as MDR reversal agents.
Schmidt M; Teitge M; Castillo ME; Brandt T; Dobner B; Langner A
Arch Pharm (Weinheim); 2008 Oct; 341(10):624-38. PubMed ID: 18816589
[TBL] [Abstract][Full Text] [Related]
14. [Chemoresistance in ovarian cancer. State of the art and future prospects].
Katsaros D; Fracchioli S; Arese P; Enria R; Cassinelli P; Mingrone K; Piccinno R; Rigault de la Longrais IA; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):483-99. PubMed ID: 10767997
[TBL] [Abstract][Full Text] [Related]
15. A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence.
Sawicka M; Kalinowska M; Skierski J; Lewandowski W
J Pharm Pharmacol; 2004 Sep; 56(9):1067-81. PubMed ID: 15324475
[TBL] [Abstract][Full Text] [Related]
16. First Annual Pezcoller Symposium. Drug resistance--mechanisms and reversal.
Mihich E
Cancer Res; 1989 Dec; 49(24 Pt 1):7168-71. PubMed ID: 2582457
[No Abstract] [Full Text] [Related]
17. Cancer chemotherapy.
McElwain TJ
Clin Oncol; 1980 Mar; 6(1):85-6. PubMed ID: 7371238
[No Abstract] [Full Text] [Related]
18. Chimeric fusion proteins--diphtheria toxin-based.
Frankel AE; Powell BL; Vallera DA; Neville DM
Curr Opin Investig Drugs; 2001 Sep; 2(9):1294-301. PubMed ID: 11717818
[TBL] [Abstract][Full Text] [Related]
19. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.
Farrell NP
Semin Oncol; 2004 Dec; 31(6 Suppl 14):1-9. PubMed ID: 15726528
[TBL] [Abstract][Full Text] [Related]
20. Cancer chemotherapy 1990.
Bagshawe KD
Trans Med Soc Lond; 1989-1990; 106():42-50. PubMed ID: 2562620
[No Abstract] [Full Text] [Related]
[Next] [New Search]
